Cibc World Markets Corp Makes New $576,000 Investment in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Cibc World Markets Corp purchased a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 6,444 shares of the medical equipment provider’s stock, valued at approximately $576,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB acquired a new stake in Lantheus during the 3rd quarter worth about $25,000. Kestra Investment Management LLC acquired a new stake in Lantheus during the 4th quarter worth about $27,000. UMB Bank n.a. grew its position in Lantheus by 31.5% during the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider’s stock worth $50,000 after purchasing an additional 134 shares during the period. World Investment Advisors LLC acquired a new stake in Lantheus during the 3rd quarter worth about $60,000. Finally, Parkside Financial Bank & Trust grew its position in Lantheus by 49.4% during the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider’s stock worth $76,000 after purchasing an additional 280 shares during the period. 99.06% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on LNTH shares. JMP Securities restated a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a research report on Tuesday, January 14th. The Goldman Sachs Group started coverage on Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 target price on the stock. Truist Financial raised their target price on Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a research report on Thursday, February 27th. Finally, B. Riley dropped their target price on Lantheus from $127.00 to $122.00 and set a “buy” rating on the stock in a research report on Friday. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $129.43.

Lantheus Trading Down 1.2 %

Shares of Lantheus stock opened at $97.71 on Friday. The firm has a market capitalization of $6.69 billion, a PE ratio of 16.26 and a beta of 0.38. Lantheus Holdings, Inc. has a twelve month low of $57.92 and a twelve month high of $126.89. The firm’s 50-day moving average price is $92.67 and its 200 day moving average price is $96.58.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). The company had revenue of $391.11 million during the quarter, compared to analysts’ expectations of $376.61 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. On average, sell-side analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

Insiders Place Their Bets

In other Lantheus news, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total value of $1,005,200.00. Following the transaction, the chief financial officer now directly owns 113,860 shares of the company’s stock, valued at $11,445,207.20. This trade represents a 8.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Mary Anne Heino sold 53,107 shares of the firm’s stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares in the company, valued at $41,551,645.65. This trade represents a 10.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 64,109 shares of company stock valued at $6,110,806 in the last ninety days. 1.50% of the stock is currently owned by corporate insiders.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.